Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma

Journal Article

BACKGROUND. Transforming growth factor-β1 (TGF-β1) is a multifunctional factor and is known to affect tumor growth in malignant tumors. The effects of TGF-β1 on angiogenesis, stromal formation, and immune function suggest its possible involvement in tumor progression. The authors examined whether TGF-β1 levels may be correlated with angiogenesis, clinicopathologic factors, and survival in patients with surgically resected lung carcinoma. METHODS. TGF-β1 protein was extracted from 53 nonsmall cell lung carcinoma tissue samples (19 squamous cell carcinomas, 33 adenocarcinomas, and 1 adenosquamous cell carcinoma), and its level was measured by enzyme-linked immunosorbent assay. To assess tumor angiogenesis, microvessel density (MVD) was determined by CD31 immunostaining. RESULTS. The protein level of TGF-β1 was 289 picograms per milligram of protein (pg/mg protein), ranging from 94 pg/mg protein to 584 pg/mg protein. The TGF-β1 protein level was significantly higher in patients with lymph node metastasis compared with patients who were without lymph node metastasis (P = 0.02), and the TGF-β1 protein level was significantly higher in patients with Stage III disease (TNM classification) compared with patients who had Stage I and II disease (P = 0.03). There was no significant correlation between the TGF-β1 protein level and any of the other clinicopathologic factors that were considered. A significant positive correlation between TGF-β1 protein level and MVD was noted (P < 0.01). Furthermore, in patients with adenocarcinoma, a significant correlation between TGF-β1 protein level and prognosis was detected by multivariate analysis (P = 0.028). CONCLUSIONS. TGF-β1 seems to affect tumor angiogenesis and to play an important role in tumor progression in patients with nonsmall cell lung carcinoma. Furthermore, the TGF-β1 protein level may be an independent predictor of survival in patients with adenocarcinoma of the lung. © 2001 American Cancer Society.

Full Text

Duke Authors

Cited Authors

  • Vollmer, RT

Published Date

  • 2001

Published In

Volume / Issue

  • 91 / 5

Start / End Page

  • 964 - 971

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O